Bladder Cancer Diagnostics Market: By Type of Condition (Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Other Rare Types), By Type of Test (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Bladder Ultrasound), By End User (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Geography.  

Purchase Option

$ 4400
$ 6600
$ 8900

Bladder cancer diagnostics market size was valued at USD 372.1 Mn in 2022 and is expected to grow at 5.2% Compound Annual Growth Rate (CAGR) from 2023 to 2029. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as Transitional Cell Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma..According to the National Institute of Health, approximately 45,000 men and 17,000 women per year are diagnosed with bladder cancer only in U.S. Globally the market for bladder cancer is increasing rapidly and is expected to grow rapidly from 2016 to 2022. According to The American Cancer Society's estimates for bladder cancer in the United States for 2017 are about 79,030 new cases of bladder cancer (about 60,490 in men and 18,540 in women) were diagnosed and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women) are reporting. Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer diagnostics. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer diagnostics are some of the latest trends that have been observed in the market.

Bladder Cancer Diagnostics Market Key Developments: 
  • In May 2017. Roche Ltd. received USFDA approval for its VENTENA PD-L1 biomarket test pertaining to bladder cancer diagnosis. In 2016, Pacific Edge Limited launched officially its third bladder cancer diagnostic test Cxbladder Monitor in U.S.

Bladder Cancer Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Bladder Cancer Diagnostics Market Dynamics

Increasing incidence rate of bladder cancer cases, technological advancements and innovations with regard to the diagnosis of bladder cancer, government initiatives, the rise in aging of the population, and advanced health care services are expected to drive the market for bladder cancer diagnostics globally. In addition, the rise in awareness about bladder diseases, their available options for diagnosis in the market, and increasing health care expenditure are driving the global market for bladder cancer diagnostics. However, the rise in a number of patent expirations, asymptomatic nature of the disease, high cost associated tests, lack of awareness of the technologies factors restraining the revenue growth of the global bladder cancer diagnostics market over the forecast period.

Key Features of the Reports

  • The bladder cancer diagnostics market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Bladder Cancer Diagnostics Market Segmentation

By Type of Condition
  • Transitional cell bladder cancer
  • Invasive bladder cancer
  • Superficial bladder cancer
  • Squamous cell bladder cancer
  • Other Rare Types
By Type of Test
  • Biopsy
  • Urine Cytology
  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
By End User
  • Diagnostic Centers
  • Hospitals
  • Ambulatory Surgical Center
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Afric

Frequently Asked Questions

The bladder cancer diagnostics market is projected to expand at a CAGR of 5.7% during the forecast period  

Abbott Laboratories (U.S), Pfizer (U.S), Sanofi S.A (France), Merck & Co., Inc. (U.S), Novartis (Switzerland)

North America is the fastest-growing region for the bladder cancer diagnostics market

1. Executive Summary
2. Global Bladder Cancer Diagnostics Market Introduction 
2.1.Global Bladder Cancer Diagnostics Market  - Taxonomy
2.2.Global Bladder Cancer Diagnostics Market  - Definitions
2.2.1.Type of Condition
2.2.2.Type of Test
2.2.3.End User
2.2.4.Region
3. Global Bladder Cancer Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Bladder Cancer Diagnostics Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Bladder Cancer Diagnostics Market  By Type of Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Transitional cell bladder cancer
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Invasive bladder cancer
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Superficial bladder cancer
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Squamous cell bladder cancer
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Other Rare Types
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6. Global Bladder Cancer Diagnostics Market  By Type of Test, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Biopsy
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Urine Cytology
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Cystoscopy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Bladder Ultrasound
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Urinalysis
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7. Global Bladder Cancer Diagnostics Market  By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Diagnostic Centers
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Hospitals
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Ambulatory Surgical Center
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Bladder Cancer Diagnostics Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Bladder Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type of Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Transitional cell bladder cancer
9.1.2.Invasive bladder cancer
9.1.3.Superficial bladder cancer
9.1.4.Squamous cell bladder cancer
9.1.5.Other Rare Types
9.2.  Type of Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Biopsy
9.2.2.Urine Cytology
9.2.3.Cystoscopy
9.2.4.Bladder Ultrasound
9.2.5.Urinalysis
9.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Diagnostic Centers
9.3.2.Hospitals
9.3.3.Ambulatory Surgical Center
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Bladder Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type of Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Transitional cell bladder cancer
10.1.2.Invasive bladder cancer
10.1.3.Superficial bladder cancer
10.1.4.Squamous cell bladder cancer
10.1.5.Other Rare Types
10.2.  Type of Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Biopsy
10.2.2.Urine Cytology
10.2.3.Cystoscopy
10.2.4.Bladder Ultrasound
10.2.5.Urinalysis
10.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Diagnostic Centers
10.3.2.Hospitals
10.3.3.Ambulatory Surgical Center
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11. Asia Pacific (APAC) Bladder Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type of Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Transitional cell bladder cancer
11.1.2.Invasive bladder cancer
11.1.3.Superficial bladder cancer
11.1.4.Squamous cell bladder cancer
11.1.5.Other Rare Types
11.2.  Type of Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Biopsy
11.2.2.Urine Cytology
11.2.3.Cystoscopy
11.2.4.Bladder Ultrasound
11.2.5.Urinalysis
11.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Diagnostic Centers
11.3.2.Hospitals
11.3.3.Ambulatory Surgical Center
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Bladder Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Type of Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Transitional cell bladder cancer
12.1.2.Invasive bladder cancer
12.1.3.Superficial bladder cancer
12.1.4.Squamous cell bladder cancer
12.1.5.Other Rare Types
12.2.  Type of Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Biopsy
12.2.2.Urine Cytology
12.2.3.Cystoscopy
12.2.4.Bladder Ultrasound
12.2.5.Urinalysis
12.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Diagnostic Centers
12.3.2.Hospitals
12.3.3.Ambulatory Surgical Center
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Bladder Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Type of Condition Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Transitional cell bladder cancer
13.1.2.Invasive bladder cancer
13.1.3.Superficial bladder cancer
13.1.4.Squamous cell bladder cancer
13.1.5.Other Rare Types
13.2.  Type of Test Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Biopsy
13.2.2.Urine Cytology
13.2.3.Cystoscopy
13.2.4.Bladder Ultrasound
13.2.5.Urinalysis
13.3.  End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Diagnostic Centers
13.3.2.Hospitals
13.3.3.Ambulatory Surgical Center
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1. Abbott Laboratories (U.S)
14.2.2. Pfizer (U.S)
14.2.3. Ariad Pharmaceuticals, Inc. (U.S)
14.2.4. Sanofi S.A (France)
14.2.5. Merck & Co., Inc. (U.S)
14.2.6. Novartis (Switzerland)
14.2.7. Becton, Dickinson & Co. (U.S)
14.2.8. Siemens Healthcare Inc. (Germany)
14.2.9. Eli Lilly and Co (U.S)
14.2.10. Hoffman-La Roche Ltd. (Switzerland)
14.2.11. AstraZeneca plc (UK)
14.2.12. GlaxoSmithKline Plc., etc. (UK)
14.2.13. Bristol-Myers Squibb (U.S)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories (U.S)
  • Pfizer (U.S)
  • Ariad Pharmaceuticals, Inc. (U.S)
  • Sanofi S.A (France)
  • Merck & Co., Inc. (U.S)
  • Novartis (Switzerland)
  • Becton, Dickinson & Co. (U.S)
  • Siemens Healthcare Inc. (Germany)
  • Eli Lilly and Co (U.S)
  • Hoffman-La Roche Ltd. (Switzerland)
  • AstraZeneca plc (UK)
  • GlaxoSmithKline Plc., etc. (UK)
  • Bristol-Myers Squibb (U.S)

Adjacent Markets